Receptor Guanylyl Cyclase C and Cyclic GMP in Health and Disease: Perspectives and Therapeutic Opportunities
Overview
Affiliations
Receptor Guanylyl Cyclase C (GC-C) was initially characterized as an important regulator of intestinal fluid and ion homeostasis. Recent findings demonstrate that GC-C is also causally linked to intestinal inflammation, dysbiosis, and tumorigenesis. These advances have been fueled in part by identifying mutations or changes in gene expression in GC-C or its ligands, that disrupt the delicate balance of intracellular cGMP levels and are associated with a wide range of clinical phenotypes. In this review, we highlight aspects of the current knowledge of the GC-C signaling pathway in homeostasis and disease, emphasizing recent advances in the field. The review summarizes extra gastrointestinal functions for GC-C signaling, such as appetite control, energy expenditure, visceral nociception, and behavioral processes. Recent research has expanded the homeostatic role of GC-C and implicated it in regulating the ion-microbiome-immune axis, which acts as a mechanistic driver in inflammatory bowel disease. The development of transgenic and knockout mouse models allowed for in-depth studies of GC-C and its relationship to whole-animal physiology. A deeper understanding of the various aspects of GC-C biology and their relationships with pathologies such as inflammatory bowel disease, colorectal cancer, and obesity can be leveraged to devise novel therapeutics.
Targeting Invasion: The Role of MMP-2 and MMP-9 Inhibition in Colorectal Cancer Therapy.
Shoari A, Ashja Ardalan A, Dimesa A, Coban M Biomolecules. 2025; 15(1).
PMID: 39858430 PMC: 11762759. DOI: 10.3390/biom15010035.
Mohammed F, Baban R, Jasim M J Pharm Bioallied Sci. 2024; 16(Suppl 1):S406-S408.
PMID: 38595491 PMC: 11000992. DOI: 10.4103/jpbs.jpbs_632_23.
Breaking Down Barriers: Epithelial Contributors to Monogenic IBD Pathogenesis.
Ouahed J, Griffith A, Collen L, Snapper S Inflamm Bowel Dis. 2024; 30(7):1189-1206.
PMID: 38280053 PMC: 11519031. DOI: 10.1093/ibd/izad319.
Piroozkhah M, Aghajani A, Jalali P, Shahmoradi A, Piroozkhah M, Tadlili Y Front Oncol. 2023; 13:1277265.
PMID: 37927469 PMC: 10623427. DOI: 10.3389/fonc.2023.1277265.
Velez Lopez A, Waddell A, Antonacci S, Castillo D, Santucci N, Ollberding N Neurogastroenterol Motil. 2023; 35(12):e14681.
PMID: 37736865 PMC: 10841278. DOI: 10.1111/nmo.14681.